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Introduction
Systemic onset juvenile idiopathic arthritis (sJIA) is an
acquired auto-inflammatory disease characterized by
systemic inflammation and innate immune activation
reflected in uncontrolled production of cytokines such
as IL-1, IL-6 and IL-18. In sJIA, NK cell function
is severely hampered despite high levels of IL-18.
We recently found that defective phosphorylation of the
IL-18 receptor beta is responsible for the deficient
IL-18-NK cell axis in sJIA.
Objectives
Given the strong homology between the IL-1 and the
IL-18 receptor we questioned whether treatment with
rIL-1RA (Anakinra) may directly down regulate IL-18
production and restore the IL-18 signaling cascade in
NK cells and, if so, whether this relates to the clinical
improvement observed in sJIA patients. Therefore we
treated 15 consecutive patients with newly onset sJIA,
before start of steroids.
Methods
Clinical (ACRped) and laboratory parameters (NK Cell
activity, cytokine levels) were analyzed during 90 days
after initial start of rIL-1RA treatment. To study binding
interaction between rIL-1RA and both the IL-1R and
the IL-18R a human cell line (KG1) was used.
Results
We show that patients with sJIA have increased inflam-
masome activation leading to elevated IL-18 levels.
Treatment with recombinant rIL-1RA in steroid naïve
newly onset sJIA patients led to rapid resolution of clinical
features in 87% of patients. In vitro, rIL-1RA directly
antagonized IL-18 signaling and lead to normalization of
both inflammasome activation and IL-18 levels. Finally, in
vivo first line treatment with rIL-1RA in sJIA patients led
to a normalization of both IL-18 levels and inflammasome
activation and a restoration of the deficient IL-18-NK cell
axis, correlating with a favorable clinical response in these
patients.
Conclusion
The rapid clinical efficacy of early treatment with rIL-1RA
in sJIA is accompanied by a restoration of the IL-18-NK-
cell axis in sJIA. These data provide biological support
for the use of rIL-1RA sJIA patients early in the disease
course as first line treatment, as it directly interferes with
the deficient IL-18-NK cell axis which may lead to a
intrinsically change in the course of the disease.
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